Journal: JCI insight
Article Title: Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose.
doi: 10.1172/jci.insight.166713
Figure Lengend Snippet: Figure 2. Exogenous cBIN1 normalizes membrane microdomains at t-tubules. (A) Representative transmission electron microscopy images of post- treatment hearts (scale bar: 1 μm) from each group (left). Quantification of the degree of contour of t-tubules (n = 100–101 t-tubules from 16–40 images of 2–3 myocardial sections and 3 hearts from each group). Data are presented as percentage of t-tubules. χ2 test was used to compare t-tubule contour between groups. *** indicates P < 0.001 for db/m + GFP versus db/db + GFP; ††† indicates P < 0.001 for db/db + GFP versus db/db + cBIN1. (B) Western blots of cBIN1, SERCA2a, CaV1.2, RyR2, GLUT4, and IRAP in total cardiac microsome and sucrose-gradient isolated TT/jSR fraction (F4) from each group (n = 5 hearts per group). (C) Representative spinning disc confocal images of posttreatment mouse myocardium with power spectrum analysis of boxed areas, and quantification of SERCA2a peak power density at t-tubules (n = 35–44 cells from 3 hearts per group). Nonparametric Kruskal-Wallis test fol- lowed by Dunn’s test was used for comparison between selected pairs. *, **, *** indicates P < 0.05, 0.01, and 0.001, respectively, for comparison versus db/m + GFP; †, ††, ††† indicates P < 0.05, 0.01, 0.001, respectively, for comparison between db/db + GFP and db/db + cBIN1.
Article Snippet: For V5, SERCA2a, GLUT4, and IRAP labeling, permeabilized and blocked tissue sections or fixed cardiomyocytes were incubated with primary antibodies against V5 (V8317-2MC, Sigma-Aldrich), SERCA2a (ab2861, Abcam), GLUT4 (4670-1725GA, Bio-Rad Laboratories), or IRAP (6918S, Cell Signaling Technology) overnight at 4°C.
Techniques: Membrane, Transmission Assay, Electron Microscopy, Western Blot, Isolation, Comparison